Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes

BACKGROUND: Linagliptin is an oral antihyperglycemic agent that selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 increases the levels of the incretin hormones glucagon-like peptide and glucose-dependent insulinotropic polypeptide by preventing their degradation. OB...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoimark, Lene, Laursen, Torben, Rungby, Jørgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430084/
https://www.ncbi.nlm.nih.gov/pubmed/22952411
http://dx.doi.org/10.2147/DMSO.S16288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430084/
https://www.ncbi.nlm.nih.gov/pubmed/22952411
http://dx.doi.org/10.2147/DMSO.S16288

Ejemplares similares